Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
QScreen AI Inc. develops artificial-intelligence health screening technology for clinical, correctional, occupational, and institutional settings. Company news centers on the QAI Platform, which combines physiological signals from a standard camera, passive voice analysis, and structured clinical intake workflows to support real-time screening and documented intake outputs.
Recurring updates cover platform integration, internal validation work, patent activity, commercialization efforts in North American institutional and workforce markets, strategic advisory and contractor relationships, and financing actions tied to deployment and working capital. The company also reports on clinical instruments used within its intake workflows, including CIWA-Ar, COWS, and C-SSRS.
Predictmedix has appointed Kingswood Capital Markets to facilitate its potential NASDAQ listing under the symbol PMEDF. This move aims to enhance liquidity and capital market exposure. The listing application is subject to various regulatory requirements, including market maker retention and SEC registration. While this uplisting could significantly support Predictmedix's AI healthcare initiatives, there is no guarantee of NASDAQ acceptance. The company is dedicated to developing non-invasive AI tools for detecting impairment and screening for infectious diseases.
Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) has announced a letter of intent to acquire Symp2Pass Inc. for approximately $5 million. The acquisition aims to enhance Predictmedix's AI-powered health screening solutions, capitalizing on Symp2Pass's strong revenue generation of $2.27 million in 2020. Predictmedix expects this strategic move will broaden its market reach, improve data collection, and increase revenue through innovative product integration. The acquisition is subject to customary closing conditions and expected to finalize within 30-60 days.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced closing a non-brokered private placement raising $1,090,085 by issuing 3,114,529 units at $0.35 each. Each unit includes one common share and one warrant with an exercise price of $0.50 for two years. The company is expanding operations in marketing, hiring, and R&D following a successful product deployment at a Superbowl after-party, enhancing visibility. Funds will aid in developing AI tools for health and safety solutions in workplaces, amidst rising demand for infectious disease screening technology.
Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) has completed a successful deployment of its Safe Entry Stations in Tampa Bay, marking its entry into the live event space. The stations scanned over 6,000 individuals at VIP Super Bowl events, providing rapid, non-invasive symptom screening with an average response time of 3-4 seconds per scan. The technology identified one COVID-19 case, demonstrating its effectiveness. The deployment received positive media coverage, with endorsements from event organizers praising its superior safety measures.
PredictMedix Inc. (CSE:PMED)(OTCQB:PMEDF) has partnered with Versus Systems, Inc. to innovate tools for clinical trials, highlighted by a letter of intent signed on September 29. The partnership aims to integrate Versus’ rewards platform with PredictMedix’s remote patient monitoring technology, facilitating patient recruitment and compliance in clinical trials, a sector valued at approximately $40 billion. This initiative responds to the challenges posed by the COVID-19 pandemic, which emphasizes the need for remote patient monitoring and data integrity in clinical research.
Summary not available.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) has initiated the deployment of its COVID-19 symptom mass screening technology at Flow Water and a 24-hour pharmacy in Montreal. This partnership, outlined on August 17, 2020, aims to enhance health measures in essential businesses to mitigate COVID-19 risks.
The technology, implemented in collaboration with JUICEWORKS EXHIBITS, is designed to provide an extra layer of safety for employees and customers. The pharmacy's deployment is expected within 2-3 weeks, addressing health safety in a critical retail environment.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announces the deployment of its COVID-19 and impairment screening technology at Indian Oil Corporation Ltd, a Fortune 500 company. The deployment will begin in 3-4 weeks, marking Predictmedix's entry into the Oil & Gas sector. Additionally, the company appointed Kiran Kumari to its advisory board for business development in the Asia Pacific region. Predictmedix also filed a US patent application for a healthcare provider reward management system, further enhancing its telehealth capabilities. The company aims to address health safety across workplaces.